Craig D. Boyle Ph.D.

Craig Boyle assists in the drafting and prosecution of U.S. and international patent applications, as well as freedom to operate and patentability analyses for the pharmaceutical industry.  Prior to joining Jones Day, he spent 16 years as a medicinal chemist at Schering-Plough and Merck. In roles ranging from laboratory scientist to cross-functional team leader, he successfully designed, synthesized, and advanced several novel drug candidates to clinical trials and was responsible for organization of research and patent strategies. He also performed competitive landscape analyses for several early-stage drug discovery programs, aided in-house counsel with preparation of patent applications, and advised on USPTO office actions. Craig's life science research experience spans several disease areas, including central nervous system, cardiovascular, and metabolic disorders.

Craig has been recognized with several awards, including the Research & Development Council of New Jersey Thomas Alva Edison Patent Award for the discovery of late phase clinical Parkinson's disease treatments and the Schering-Plough President's Award for the discovery of a novel Alzheimer's disease therapy. He is coinventor of approximately 20 issued U.S. patents and 30 PCT applications and has been a peer reviewer and author of numerous scientific articles. Additionally, Craig has given several external scientific presentations, including a visiting lecture at Columbia University and a "First-Time Disclosures of Clinical Candidates" American Chemical Society National Meeting Address on the discovery of the phase II cardiovascular compound dasantafil that was featured in Chemical & Engineering News. [1]